Log In
Print
BCIQ
Print
Print this Print this
 

GAL-021

  Manage Alerts
Collapse Summary General Information
Company Galleon Pharmaceuticals Inc.
DescriptionPotassium channel KCa1.1 (KCNMA1; SLO) blocker
Molecular Target Potassium channel KCa1.1 (KCNMA1) (SLO)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsTreat opioid-induced respiratory depression and related complications, including sleep apnea; Treat respiratory depression
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today